Innate Pharma S.A.
Innate Pharma S.A. (IPHA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ipha · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Innate Pharma S.A. (IPHA) measures how much investors pay for each dollar of the company's trailing earnings. IPHA's current PE ratio of N/A is calculated by dividing its stock price of $1.76 by its TTM earnings per share of -$0.54.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Innate Pharma S.A.You IPHA | $165M | N/A | — | -$0.54 |
 Applied Therapeutics, Inc. APLT | $15M | N/A | — | -$0.76 |
 Compugen Ltd. CGEN | $193M | 4.04x | — | $0.38 |
 Corbus Pharmaceuticals Holdings, Inc. CRBP | $95M | N/A | — | -$5.90 |
 Cardiff Oncology, Inc. CRDF | $103M | N/A | — | -$0.69 |
 Cybin Inc. CYBN | $413M | N/A | — | -$0.61 |
 Elicio Therapeutics, Inc. ELTX | $259M | N/A | — | -$2.58 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.55 | — | |
2024-12-31 FY2024 | — | $-0.61 | — | |
2023-12-31 FY2023 | — | $-0.09 | — | |
2022-12-31 FY2022 | — | $-0.73 | — | |
2021-12-31 FY2021 | — | $-0.66 | — | |
2020-12-31 FY2020 | — | $-0.81 | — | |
2019-12-31 FY2019 | — | $-0.31 | — | |
2018-12-31 FY2018 | 101.70x | $0.05 | — | |
2017-12-31 FY2017 | — | $-0.89 | — | |
2016-12-31 FY2016 | 24.48x | $0.23 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Innate Pharma S.A. (IPHA) measures how much investors pay for each dollar of the company's trailing earnings. IPHA's current PE ratio of N/A is calculated by dividing its stock price of $1.76 by its TTM earnings per share of -$0.54.
Frequently asked questions
IPHA pe ratio · 6 questionsIPHA's current PE ratio is N/A as of 2026-06-08, based on a stock price of $1.76 and TTM EPS of -$0.54. Data sourced from Financial Modeling Prep via IPHA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Innate Pharma S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08